Developer docs
API playgroundTry for free, no card

Search company profiles

Sintetica

Full company profile

uuid0009rvh

Namestring
Sintetica
Legal namestring
SINTETICA SA
Websiteurl
sintetica.com
Company typeenum
Private
Founded yearint
1921
Descriptiontext

Sintetica SA is a Swiss specialty pharmaceutical company founded in 1921 and headquartered in Mendrisio, Switzerland, focused on the development, manufacturing, and commercialization of sterile injectable solutions. Its portfolio spans anaesthesia, pain management, neuromodulation, and intensive care, with a flagship Premix® platform that delivers premixed, ready-to-use, preservative-free formulations designed to eliminate bedside drug manipulation. The company operates two FDA-approved manufacturing sites in Switzerland — Mendrisio (ampoules) and Couvet (vials and infusion bags) — with combined annual capacity of approximately 90 million ampoules, 8 million vials, and 5 million infusion bags, and markets 250+ products across more than 50 countries.

Sintetica's business model is a hybrid of direct sales and licensed distribution. In Switzerland, Germany, and Austria, specialized national sales teams sell directly to hospitals and clinicians; outside these markets, the company relies on licensing and distribution partnerships with top-tier international players. Revenue (2024 disclosure) is geographically diversified at 32% Switzerland, 25% Germany & Austria, 25% United States, and 18% Rest of World, and split 41% B2B and 59% B2C across therapeutic areas led by Emergency & Intensive Care (45%), Anaesthesia (24%), Analgesics (22%), and Neuromodulation (9%). Notable branded assets include Ampres® (the first chloroprocaine approved for spinal anaesthesia in Europe), Takipril® (hyperbaric prilocaine), and IHEEZO™ (an ophthalmic gel licensed to Harrow in the U.S. and Canada, protected by Orange Book-listed patents until 2038).

The company has been majority-owned by French private equity firm Ardian since May 2019, with a confirmed 60 million CHF four-year investment plan supporting globalization. Sintetica has 16 granted patents, an Innovation Cluster combining pharmaceutical, medical, and industrial development, and a 2024 management refresh including a new Executive Chairman/CEO (Dr. Hubert Puech d'Alissac), CFO (Dr. Luca Scavo), and independent director (Brendan O'Grady, formerly of Teva and Glenmark) — moves consistent with a commercial scaling and U.S. market entry strategy that began with the 2023 FDA approval of the Couvet site.

Short descriptiontext

Sintetica is a Swiss specialty pharmaceutical company that develops and manufactures sterile injectable drugs in anaesthesia, pain management, neuromodulation, and intensive care, selling through direct hospital sales in DACH and licensed distributors across 50+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersMendrisio, Switzerland
HQ citystring
Mendrisio
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sterile injectable drugs, pharmaceutical manufacturing, anaesthesia medications, pain management drugs, intensive care pharmaceuticals
Industry3 codes
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIABAC
Sterile Injectable Generics
SECONDARYHLAIABAL
Generic Hospital & Institutional Products
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Injectable Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Direct Pharmaceutical Sales
TypeOne Time License
Description

Sintetica directly sells and markets its pharmaceutical products (anaesthesia, pain management, neuromodulation, intensive care) in Switzerland, Germany, and Austria through specialized national sales teams. Products include over 250 formulations sold in 50+ countries.

sintetica.com
2Licensing and Distribution Partnerships
TypeLicensing Royalties
Description

Sintetica licenses its products to commercial partners worldwide. The company runs sales subsidiaries in selected European markets and partners with leading distributors around the world for markets outside its direct presence.

sintetica.com
3International Business Development
TypeOne Time License
Description

The company offers a dynamic portfolio of selected branded and generic products developed to address niche and unmet clinical needs, built through strong and long-lasting alliances with international partners.

sintetica.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Premix
Description

Premixed medicines that increase safety of therapy by direct administration without previous dilution, reducing time and complexity of drug preparation.

sintetica.com
+2 more records
Core offering1 text field

Sintetica researches, develops, manufactures, and markets sterile injectable pharmaceutical products in ampoules, vials, and IV bags for anaesthesia, pain management, neuromodulation, and intensive care. The portfolio includes over 250 marketed formulations across proprietary brands (Premix®, Ampres®, Takipril®, IHEEZO™) and generic injectable drugs, produced at two FDA-approved Swiss manufacturing sites and distributed directly in Switzerland, Germany, and Austria and through licensing partners in 50+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • FDA approval for Couvet production site in 2023 with no deviations found
+1 more record
Product overview1 text field

Sintetica is a Swiss pharmaceutical company that develops and manufactures a comprehensive portfolio of injectable medications for anesthesia, pain management, neuromodulation, and intensive care. The company operates two FDA-approved production sites in Switzerland (Mendrisio and Couvet) and produces liquid sterile injectable solutions in ampoules, vials, and IV bags. Their core products include 14 main injectable medications (Baclofen, Bupivacaine, Chloroprocaine, Droperidol, Ephedrine, Glycopyrrolate/Neostigmine, Heparin, Hydromorphone, Ketamine, Midazolam, Noradrenaline, Paracetamol, Phenylephrine, and Ropivacaine). Key branded offerings include IHEEZO™ ophthalmic gel and the Premix® platform for ready-to-use formulations. The company also focuses on therapeutic approaches like One Day Surgery and Enhance Intrathecal Therapy, targeting day surgery, perioperative care, and neuromodulation applications.

Product and service17 records
1Baclofen Inj
CategoryNeuromodulation / Pain Management Injectables
Description

Injectable muscle relaxant medication used in pain management and neuromodulation therapies, supplied to hospitals for intrathecal and pain care applications.

2Bupivacaine Inj
CategoryLocal Anaesthetic Injectables
Description

Long-acting local anaesthetic injection used for regional anaesthesia in surgical procedures.

3Chloroprocaine Inj / Gel (Ampres®)
CategoryLocal Anaesthetic Injectables
Description

Short-acting local anaesthetic in injectable and gel formulations, including the Ampres® spinal formulation and chloroprocaine-based ophthalmic gels supplied to hospitals and surgical centers.

4Droperidol Inj
CategoryPeri-Operative Injectables
Description

Antipsychotic and antiemetic injectable medication used in anaesthesia and perioperative care.

5Ephedrine HCl Inj
CategoryPeri-Operative Injectables
Description

Vasopressor injection used for treatment of hypotension during anaesthesia.

6Glycopyrrolate & Neostigmine Inj
CategoryPeri-Operative Injectables
Description

Combination injection used to reverse neuromuscular blockade after surgery.

7Heparine Inj
CategoryIntensive Care Injectables
Description

Anticoagulant injection used in intensive care and surgical settings.

8Hydromorphone Inj
CategoryAnalgesic Injectables
Description

Potent opioid analgesic injection for severe pain management in perioperative and critical-care settings.

9Ketamine HCl Inj
CategoryAnaesthetic Injectables
Description

Dissociative anaesthetic injection used for induction and maintenance of anaesthesia and in pain management.

10Midazolam Inj
CategoryAnaesthetic Injectables
Description

Benzodiazepine injection used for sedation, anaesthesia induction, and anxiety management in critical care.

11Noradrenaline Inj
CategoryIntensive Care Injectables
Description

Vasoconstrictor emergency life-saving drug used for treatment of hypotonia and shock states.

12Paracetamol Inj
CategoryAnalgesic Injectables
Description

Intravenous analgesic injection for pain and fever management in hospital settings.

13Phenylephrine HCl Inj
CategoryPeri-Operative Injectables
Description

Alpha-adrenergic agonist injection used for treatment of hypotension during anaesthesia.

14Ropivacaine HCl Inj
CategoryLocal Anaesthetic Injectables
Description

Long-acting local anaesthetic injection suitable for regional anaesthesia and pain management, including day-surgery applications.

15IHEEZO™
CategoryOphthalmic Anaesthetic Gel
Description

Chloroprocaine hydrochloride ophthalmic gel 3% for ocular surface anaesthesia. Sterile, single-patient-use, physician-administered preparation containing no preservatives, sold to ophthalmology clinics and hospitals.

16Premix® Platform
CategoryReady-to-Use Injectable Platform
Description

Proprietary platform of premixed, ready-to-use injectable medicines that increase therapy safety by enabling direct administration without prior dilution, reducing time and complexity of drug preparation in hospital settings.

17Takipril®
CategorySpinal Anaesthetic Injectables
Description

Patented hyperbaric Prilocaine formulation for spinal administration in short-duration surgeries, sold to hospitals for day surgery and spinal anaesthesia use.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Meduna GmbH
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2013-05-08
Description

Sintetica acquired Meduna GmbH in 2013 and established Sintetica GmbH as its first foreign subsidiary in Germany, enabling direct service of the German and Austrian markets. In 2016, Sintetica GmbH moved to a new larger location in Münster, Westphalia.

sintetica.com
2Bioren SA (Couvet)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2005-01-01
Description

Sintetica acquired Bioren SA in 2005, one of its suppliers of vials and infusion bags, forming Sintetica-Bioren SA as the second manufacturing plant in Switzerland. Augusto Mitidieri was appointed CEO and Luca Bolzani was President of the Board following the acquisition.

sintetica.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

German-headquartered specialist in sterile injectable pharmaceuticals, anaesthesia, pain management, and clinical nutrition. Directly comparable to Sintetica in therapeutic focus (anaesthesia/pain injectables), sterile injectable manufacturing, and B2B hospital-channel commercialization across multiple geographies.

TypeDirect peer
Description

Family-owned German medical device and pharmaceutical company with a sizable sterile injectable and anaesthesia portfolio, serving hospitals globally. Overlaps directly with Sintetica on local anaesthetics, peri-operative injectables, and DACH-centered hospital commercialization.

TypeDirect peer
Description

US-based pure-play sterile injectable and IV therapy company serving hospitals and alternate-care sites. Comparable to Sintetica as a focused sterile injectable manufacturer with US regulatory depth (FDA-inspected facilities) and a similar product-form mix (bags, vials, syringes).

TypeDirect peer
Description

UK-listed specialty and injectable pharmaceutical company with a large sterile injectable generics portfolio sold to hospitals worldwide. Highly comparable to Sintetica in product form (sterile injectables), hospital channel, and international licensing/distributor model outside direct markets.

TypeBroad incumbent
Description

Global hospital-products leader with a major sterile injectable, IV solutions, and anaesthesia franchise. Overlaps with Sintetica on ampoules, vials and IV bags in the same hospital call points, though Baxter operates a much broader medical products portfolio beyond injectables.

TypeBroad incumbent
Description

World's largest pharmaceutical company, holding the legacy Hospira sterile injectable generics portfolio that competes head-to-head in anaesthetics, analgesics, and peri-operative injectables. Significantly larger than Sintetica but a direct competitor in the US hospital injectable channel that Sintetica is now entering.

TypeBroad incumbent
Description

Global leader in generic injectable pharmaceuticals, particularly anaesthesia and pain management injectables, and a direct US-market competitor through its hospital business. Brendon O'Grady, Sintetica's new independent director, previously led Teva North America; relevant executive overlap as well as product overlap.

TypeDirect peer
Description

Indian-headquartered global pharmaceutical company with a growing sterile injectable portfolio (incl. anaesthesia/analgesics) and a multi-continent commercial footprint. Comparable to Sintetica as a focused injectable pharmaceutical manufacturer scaling internationally through partnerships and direct sales.

TypeEmerging player
Description

South African pharmaceutical group with a global sterile injectable and anaesthesia presence, particularly strong in emerging markets. Comparable to Sintetica in therapeutic focus (anaesthesia/pain) and product form (sterile injectables), though a different geographic anchor.

10Sandoz (Novartis)
TypeBroad incumbent
Description

Spin-off of Novartis and one of the world's largest generic injectable pharmaceutical companies, with a broad peri-operative and hospital injectable portfolio. Comparable to Sintetica as a global sterile injectable competitor; considerably larger scale than Sintetica but a direct set of head-to-head hospital injectable products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sintetica

Injectable Pharmaceuticalssintetica.com

Sintetica is a Swiss specialty pharmaceutical company that develops and manufactures sterile injectable drugs in anaesthesia, pain management, neuromodulation, and intensive care, selling through direct hospital sales in DACH and licensed distributors across 50+ countries.

What Sintetica does

Sintetica SA is a Swiss specialty pharmaceutical company founded in 1921 and headquartered in Mendrisio, Switzerland, focused on the development, manufacturing, and commercialization of sterile injectable solutions. Its portfolio spans anaesthesia, pain management, neuromodulation, and intensive care, with a flagship Premix® platform that delivers premixed, ready-to-use, preservative-free formulations designed to eliminate bedside drug manipulation. The company operates two FDA-approved manufacturing sites in Switzerland — Mendrisio (ampoules) and Couvet (vials and infusion bags) — with combined annual capacity of approximately 90 million ampoules, 8 million vials, and 5 million infusion bags, and markets 250+ products across more than 50 countries.

Sintetica's business model is a hybrid of direct sales and licensed distribution. In Switzerland, Germany, and Austria, specialized national sales teams sell directly to hospitals and clinicians; outside these markets, the company relies on licensing and distribution partnerships with top-tier international players. Revenue (2024 disclosure) is geographically diversified at 32% Switzerland, 25% Germany & Austria, 25% United States, and 18% Rest of World, and split 41% B2B and 59% B2C across therapeutic areas led by Emergency & Intensive Care (45%), Anaesthesia (24%), Analgesics (22%), and Neuromodulation (9%). Notable branded assets include Ampres® (the first chloroprocaine approved for spinal anaesthesia in Europe), Takipril® (hyperbaric prilocaine), and IHEEZO™ (an ophthalmic gel licensed to Harrow in the U.S. and Canada, protected by Orange Book-listed patents until 2038).

The company has been majority-owned by French private equity firm Ardian since May 2019, with a confirmed 60 million CHF four-year investment plan supporting globalization. Sintetica has 16 granted patents, an Innovation Cluster combining pharmaceutical, medical, and industrial development, and a 2024 management refresh including a new Executive Chairman/CEO (Dr. Hubert Puech d'Alissac), CFO (Dr. Luca Scavo), and independent director (Brendan O'Grady, formerly of Teva and Glenmark) — moves consistent with a commercial scaling and U.S. market entry strategy that began with the 2023 FDA approval of the Couvet site.

Sintetica firmographics

Firmographics
Name
Sintetica
Legal name
SINTETICA SA
Website
https://sintetica.com
Company type
Private
Founded year
1921
Operating status
Operating
Headcount range
251–500 employees
Short description
Sintetica is a Swiss specialty pharmaceutical company that develops and manufactures sterile injectable drugs in anaesthesia, pain management, neuromodulation, and intensive care, selling through direct hospital sales in DACH and licensed distributors across 50+ countries.
Ownership category
akta.pro rank

Sintetica industry classification

Industry
Product category
Injectable Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIABAC
Sterile Injectable Generics
SECONDARYHLAIABAL
Generic Hospital & Institutional Products

Keywords

  • Sterile injectable drugs
  • Pharmaceutical manufacturing
  • Anaesthesia medications
  • Pain management drugs
  • Intensive care pharmaceuticals

Where Sintetica is headquartered

Location

Headquarters

HQ city
Mendrisio
HQ country
Switzerland
HQ region
Europe

Offices3 records

Markets served

Sintetica business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Direct Pharmaceutical Sales: Sintetica directly sells and markets its pharmaceutical products (anaesthesia, pain management, neuromodulation, intensive care) in Switzerland, Germany, and Austria through specialized national sales teams. Products include over 250 formulations sold in 50+ countries.
  2. Licensing and Distribution Partnerships: Sintetica licenses its products to commercial partners worldwide. The company runs sales subsidiaries in selected European markets and partners with leading distributors around the world for markets outside its direct presence.
  3. International Business Development: The company offers a dynamic portfolio of selected branded and generic products developed to address niche and unmet clinical needs, built through strong and long-lasting alliances with international partners.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Sintetica product offering

Product offering

Core offering

Sintetica researches, develops, manufactures, and markets sterile injectable pharmaceutical products in ampoules, vials, and IV bags for anaesthesia, pain management, neuromodulation, and intensive care. The portfolio includes over 250 marketed formulations across proprietary brands (Premix®, Ampres®, Takipril®, IHEEZO™) and generic injectable drugs, produced at two FDA-approved Swiss manufacturing sites and distributed directly in Switzerland, Germany, and Austria and through licensing partners in 50+ countries.

Product overview

Sintetica is a Swiss pharmaceutical company that develops and manufactures a comprehensive portfolio of injectable medications for anesthesia, pain management, neuromodulation, and intensive care. The company operates two FDA-approved production sites in Switzerland (Mendrisio and Couvet) and produces liquid sterile injectable solutions in ampoules, vials, and IV bags. Their core products include 14 main injectable medications (Baclofen, Bupivacaine, Chloroprocaine, Droperidol, Ephedrine, Glycopyrrolate/Neostigmine, Heparin, Hydromorphone, Ketamine, Midazolam, Noradrenaline, Paracetamol, Phenylephrine, and Ropivacaine). Key branded offerings include IHEEZO™ ophthalmic gel and the Premix® platform for ready-to-use formulations. The company also focuses on therapeutic approaches like One Day Surgery and Enhance Intrathecal Therapy, targeting day surgery, perioperative care, and neuromodulation applications.

Differentiator

Problem solved

Functional benefit

Brands

  • Premix: Premixed medicines that increase safety of therapy by direct administration without previous dilution, reducing time and complexity of drug preparation.
  • Takipril
  • Ampres

Products and services

  • Baclofen Inj Injectable muscle relaxant medication used in pain management and neuromodulation therapies, supplied to hospitals for intrathecal and pain care applications.
  • Bupivacaine Inj Long-acting local anaesthetic injection used for regional anaesthesia in surgical procedures.
  • Chloroprocaine Inj / Gel (Ampres®) Short-acting local anaesthetic in injectable and gel formulations, including the Ampres® spinal formulation and chloroprocaine-based ophthalmic gels supplied to hospitals and surgical centers.
  • Droperidol Inj Antipsychotic and antiemetic injectable medication used in anaesthesia and perioperative care.
  • Ephedrine HCl Inj Vasopressor injection used for treatment of hypotension during anaesthesia.
  • Glycopyrrolate & Neostigmine Inj Combination injection used to reverse neuromuscular blockade after surgery.
  • Heparine Inj Anticoagulant injection used in intensive care and surgical settings.
  • Hydromorphone Inj Potent opioid analgesic injection for severe pain management in perioperative and critical-care settings.
  • Ketamine HCl Inj Dissociative anaesthetic injection used for induction and maintenance of anaesthesia and in pain management.
  • Midazolam Inj Benzodiazepine injection used for sedation, anaesthesia induction, and anxiety management in critical care.
  • Noradrenaline Inj Vasoconstrictor emergency life-saving drug used for treatment of hypotonia and shock states.
  • Paracetamol Inj Intravenous analgesic injection for pain and fever management in hospital settings.
  • Phenylephrine HCl Inj Alpha-adrenergic agonist injection used for treatment of hypotension during anaesthesia.
  • Ropivacaine HCl Inj Long-acting local anaesthetic injection suitable for regional anaesthesia and pain management, including day-surgery applications.
  • IHEEZO™ Chloroprocaine hydrochloride ophthalmic gel 3% for ocular surface anaesthesia. Sterile, single-patient-use, physician-administered preparation containing no preservatives, sold to ophthalmology clinics and hospitals.
  • Premix® Platform Proprietary platform of premixed, ready-to-use injectable medicines that increase therapy safety by enabling direct administration without prior dilution, reducing time and complexity of drug preparation in hospital settings.
  • Takipril® Patented hyperbaric Prilocaine formulation for spinal administration in short-duration surgeries, sold to hospitals for day surgery and spinal anaesthesia use.

Quantifiable outcome

  • FDA approval for Couvet production site in 2023 with no deviations found
  • +1 more outcomes

Companies that use Sintetica

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles4 records

Sintetica technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Sintetica partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Meduna GmbHcoreStrategic or Co-development Partner · 8 May 2013Sintetica acquired Meduna GmbH in 2013 and established Sintetica GmbH as its first foreign subsidiary in Germany, enabling direct service of the German and Austrian markets. In 2016, Sintetica GmbH moved to a new larger location in Münster, Westphalia.
  • Bioren SA (Couvet)coreStrategic or Co-development Partner · 1 January 2005Sintetica acquired Bioren SA in 2005, one of its suppliers of vials and infusion bags, forming Sintetica-Bioren SA as the second manufacturing plant in Switzerland. Augusto Mitidieri was appointed CEO and Luca Bolzani was President of the Board following the acquisition.

Scale indicators10 records

Recent moves10 records

Expansion highlights6 records

Sintetica competitors and assessment

Company assessment

Direct peers

  • Fresenius Kabi: German-headquartered specialist in sterile injectable pharmaceuticals, anaesthesia, pain management, and clinical nutrition. Directly comparable to Sintetica in therapeutic focus (anaesthesia/pain injectables), sterile injectable manufacturing, and B2B hospital-channel commercialization across multiple geographies.
  • B. Braun: Family-owned German medical device and pharmaceutical company with a sizable sterile injectable and anaesthesia portfolio, serving hospitals globally. Overlaps directly with Sintetica on local anaesthetics, peri-operative injectables, and DACH-centered hospital commercialization.
  • ICU Medical: US-based pure-play sterile injectable and IV therapy company serving hospitals and alternate-care sites. Comparable to Sintetica as a focused sterile injectable manufacturer with US regulatory depth (FDA-inspected facilities) and a similar product-form mix (bags, vials, syringes).
  • Hikma Pharmaceuticals: UK-listed specialty and injectable pharmaceutical company with a large sterile injectable generics portfolio sold to hospitals worldwide. Highly comparable to Sintetica in product form (sterile injectables), hospital channel, and international licensing/distributor model outside direct markets.
  • Dr. Reddy's Laboratories: Indian-headquartered global pharmaceutical company with a growing sterile injectable portfolio (incl. anaesthesia/analgesics) and a multi-continent commercial footprint. Comparable to Sintetica as a focused injectable pharmaceutical manufacturer scaling internationally through partnerships and direct sales.

Broad incumbents

  • Baxter International: Global hospital-products leader with a major sterile injectable, IV solutions, and anaesthesia franchise. Overlaps with Sintetica on ampoules, vials and IV bags in the same hospital call points, though Baxter operates a much broader medical products portfolio beyond injectables.
  • Pfizer (Injectables): World's largest pharmaceutical company, holding the legacy Hospira sterile injectable generics portfolio that competes head-to-head in anaesthetics, analgesics, and peri-operative injectables. Significantly larger than Sintetica but a direct competitor in the US hospital injectable channel that Sintetica is now entering.
  • Teva Pharmaceutical Industries: Global leader in generic injectable pharmaceuticals, particularly anaesthesia and pain management injectables, and a direct US-market competitor through its hospital business. Brendon O'Grady, Sintetica's new independent director, previously led Teva North America; relevant executive overlap as well as product overlap.
  • Sandoz (Novartis): Spin-off of Novartis and one of the world's largest generic injectable pharmaceutical companies, with a broad peri-operative and hospital injectable portfolio. Comparable to Sintetica as a global sterile injectable competitor; considerably larger scale than Sintetica but a direct set of head-to-head hospital injectable products.

Emerging players

  • Aspen Pharmacare: South African pharmaceutical group with a global sterile injectable and anaesthesia presence, particularly strong in emerging markets. Comparable to Sintetica in therapeutic focus (anaesthesia/pain) and product form (sterile injectables), though a different geographic anchor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Sintetica social profiles

Digital presence

Sintetica compliance and trust

Trust signal

Compliance7 records

Sintetica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sintetica leadership team

Management profile

Number of profiles

Profiles7 records

Sintetica subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Sintetica funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sintetica M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sintetica

What does Sintetica do?

Sintetica researches, develops, manufactures, and markets sterile injectable pharmaceutical products in ampoules, vials, and IV bags for anaesthesia, pain management, neuromodulation, and intensive care. The portfolio includes over 250 marketed formulations across proprietary brands (Premix®, Ampres®, Takipril®, IHEEZO™) and generic injectable drugs, produced at two FDA-approved Swiss manufacturing sites and distributed directly in Switzerland, Germany, and Austria and through licensing partners in 50+ countries.

Is Sintetica a public or private company?

Sintetica is a private company. It is classified as private equity controlled and is currently operating.

When was Sintetica founded?

Sintetica was founded in 1921. It employs 251 to 500 people.

Where is Sintetica based?

Sintetica is headquartered in Mendrisio, Switzerland, in the Europe region.

How does Sintetica make money?

Three revenue lines are on record. Direct Pharmaceutical Sales are the primary driver. The others are licensing and Distribution Partnerships and international Business Development.

Who are Sintetica's main competitors?

Direct peers on record are Fresenius Kabi, B. Braun, ICU Medical, Hikma Pharmaceuticals and Dr. Reddy's Laboratories. Broad incumbents are Baxter International, Pfizer (Injectables), Teva Pharmaceutical Industries and Sandoz (Novartis). Aspen Pharmacare is listed as an emerging player.

Does Sintetica have an API?

No public API is recorded for Sintetica.

What industry is Sintetica in?

Sintetica's product category is Injectable Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals, with a secondary code of HLAIABAC, Sterile Injectable Generics. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireQuality, traceability and time to market improved with Sintetica's deployment of PharmaSuite MESRockwell Automation announced that Swiss pharmaceutical company Sintetica SA has adopted the FactoryTalk PharmaSuite MES manufacturing execution system at its production facility in Switzerland as part of a wider digitalization initiative. The deployment, which began as a pilot on two lines, aims to improve quality, monitoring, insights, and external interactions while reducing time to market through quicker batch reviews. Operator feedback has been positive, with the data-driven system empowering staff and reducing time spent on monitoring and recording batch information.PR NewswireSintetica US launches Lidocaine Hydrochloride Injection, USP 1%, 2% and 4%Sintetica S.A., a Swiss pharmaceutical company, has launched Lidocaine Hydrochloride Injection products in three concentrations (1%, 2%, and 4%) through its US subsidiary Sintetica US, established in Princeton, New Jersey in 2022. The launch marks Sintetica US's first commercial product and is specifically aimed at addressing a critical shortage of lidocaine in the US market. The company highlighted its ten-year track record in the US and its capacity to produce large volumes of the sterile injectable as key factors enabling it to support healthcare professionals during the supply shortfall.PR NewswireSintetica US lance le chlorhydrate de lidocaïne injectable, USP 1 %, 2 % et 4 %Sintetica S.A., a Swiss pharmaceutical company, announced the launch of lidocaine hydrochloride injectable (USP 1%, 2%, and 4%) through its newly established US subsidiary Sintetica US in Princeton, New Jersey. The product represents Sintetica US's first commercial launch and is being introduced during a critical shortage of lidocaine in the United States. The company stated it will leverage its capacity to produce large volumes of lidocaine to ensure access to this important medication while consolidating its direct presence in the US market.PR NewswireSintetica US bringt Lidocainhydrochlorid Injektionslösung, USP 1 %, 2 % und 4 % auf den MarktSintetica S.A., a Swiss international pharmaceutical company, announced the market launch of Lidocaine Hydrochloride Injection, USP in three concentrations (1%, 2%, and 4%) through its US subsidiary Sintetica US, based in Princeton, New Jersey. The product was launched on March 27, 2023, and addresses a critical shortage of this short-acting amide-type local anesthetic in the United States. The launch marks Sintetica US's first commercial product and represents a significant milestone in Sintetica's 100-year history, establishing direct market presence in the US.PR NewswireSintetica US launches Lidocaine Hydrochloride Injection, USP 1%, 2% and 4%Sintetica S.A., a Swiss pharmaceutical company, announced the launch of Lidocaine Hydrochloride Injection products (1%, 2%, and 4%) through its US subsidiary Sintetica US, established in 2022 in Princeton, New Jersey. The launch marks Sintetica US's first commercial product and is being brought to market specifically during a critical shortage of lidocaine in the United States, with Sintetica positioning itself to provide large-volume supply to address the supply gap.PR NewswireSintetica establishes US entitySintetica, a Swiss pharmaceutical company headquartered in Mendrisio specializing in injectables for pain therapy, established its US subsidiary Sintetica US in Princeton, New Jersey on July 14, 2022. The new subsidiary, led by President Frank Mullery with over 20 years of pharmaceutical industry experience, will enable Sintetica to serve both B2B and B2C markets in the United States while continuing to service existing B2B partners through current agreements. This establishment represents another step in Sintetica's 100-year growth strategy focused on international market expansion.PR NewswireSintetica establishes US entitySintetica established a US subsidiary, Sintetica US, headquartered in Princeton, New Jersey, led by President Frank Mullery. This move is part of the company's 100-year growth strategy to expand its presence in international markets, specifically targeting both B2B and B2C sectors in the United States.BenzingaFDA Approves First Branded Ocular Anesthetic In Almost 14 Years - Harrow (NASDAQ:HROW)The FDA approved Harrow Health Inc and Sintetica S.A.'s Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia, representing the first branded ocular anesthetic approved for the U.S. ophthalmic market in nearly 14 years. Iheezo is the first approved use of chloroprocaine hydrochloride in U.S. ophthalmology and was demonstrated effective in three human clinical studies, showing rapid onset of 1 to 1.5 minutes with sufficient anesthesia lasting an average of 22 minutes. The company has accelerated its market access strategy to support a commercial launch slightly ahead of the planned date at the May 2023 American Society of Cataract and Refractive Surgery meeting.PR NewswireHarrow Health erwirbt patentierten ophthalmochirurgischen Wirkstoffkandidaten von SinteticaHarrow Health, Inc. has acquired the US and Canada marketing and supply rights for AMP-100, a patented ophthalmic surgical drug candidate developed by Sintetica S.A., for surface anesthesia during procedures including cataract surgery and intravitreal injections. Sintetica plans to submit a New Drug Application to the FDA by the end of 2021, and upon approval, the active ingredient in AMP-100 would represent the first approved use of this substance in the US ophthalmology market, targeting over 10 million annual procedures in the US.PR NewswireHarrow Health acquiert un médicament expérimental breveté pour la chirurgie ophtalmique auprès de SinteticaHarrow Health, Inc. announced it has entered into an agreement with Sintetica, S.A. to acquire the US and Canada commercialization and supply rights for AMP-100, an experimental patented drug for ophthalmic surface anesthesia during procedures such as cataract surgery and intravitreal injections. A Phase 3 study successfully demonstrated AMP-100's efficacy and tolerability compared to current standard of care, with a New Drug Application (NDA) submission to the FDA planned for end of 2021. The agreement includes upfront payments, milestone payments, and unit royalties to Sintetica, while Harrow Health gains commercialization rights in the US and Canada and Sintetica retains rights in all other countries.